<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9352">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985190</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-AZA-SAID</org_study_id>
    <secondary_id>2016-000918-30</secondary_id>
    <nct_id>NCT02985190</nct_id>
  </id_info>
  <brief_title>A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders</brief_title>
  <official_title>A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II of effcicacy and tolerance of azacitidine in patients with
      myelodysplatic syndrome and steroid dependent or resistent systemic auto-immune and
      inflammatory disorders
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will be a prospective French nationwide study analyzing the effect of treatment
      with azacitidine in patients with MDS-associated SAID with steroid dependence and/or
      resistance, and its correlation with possible changes in immunological parameters
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of Myelodysplastic syndrome and systemic autoimmune and inflammatory diseases (SAID)</measure>
    <time_frame>6 months</time_frame>
    <description>Overall response rate (including partial and complete response) of systemic autoimmune and inflammatory diseases associated with Myelodysplastic syndrome after 6 cycles of azacitidine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treament-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 52 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>MDS</condition>
  <condition>Systemic Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Azacitidine 75mg/m²/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles
in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles
in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine at 75mg/m²/j for 7 days.</description>
    <arm_group_label>Azacitidine 75mg/m²/day</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must understand and voluntarily sign the informed consent form

          -  Age 18 years at the time of signing the informed consent form

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Diagnosis of MDS using the 2008 WHO classification for myeloid neoplasms as assessed
             during the screening period

          -  IPSS intermediate 2 or high, including AML with 20 to 30% marrow blasts and CMML with
             WBC&lt;13G/L and marrow blasts &gt;10%, or IPSS low or int 1 in need of treatment
             (transfusion dependent anemia resistant to ESAs and/or platelets below 30 G/l or
             below 50 G/l with bleeding or platelet transfusion requirement, and/or ANC &lt; 0.5 G/l
             with infectious complications)

          -  SAID-associated with MDS defined according to usual international criteria for each
             SAID (ie ACR criteria for systemic lupus, Chapel Hill classification for systemic
             vasculitis, etc…)

          -  Steroid dependence and/or resistance of SAID (steroid dependence being defined as the
             impossibility to decrease steroids during at least 2 months below 15 mg/day; steroid
             resistance as no response of SAID to at least 1 mg/kg/day of prednisone equivalent
             during one month)

          -  Ineligibility for allogeneic stem cell transplantation during the following 12 months

          -  No previous use of lenalidomide

          -  No previous use of hypomethylating agents

          -  Life expectancy ≥ 6 months

          -  Adequate liver function (serum transaminases ≤ 3N)

          -  Adequate renal function (creatinine clearance with MDRD formula &gt; 30 ml/min)

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not
             surgically sterile) must :

               -  Have a negative serum or urine pregnancy test within 2 weeks prior to beginning
                  treatment on this study. Lactating patients are excluded.

               -  Agree to use, and to be able to comply with, effective contraception without
                  interruption, 4 weeks before starting study drug throughout the entire duration
                  study drug therapy (including doses interruptions) and for 3 months after the
                  end of the study drug therapy.

          -  Male patients must :

               -  Agree the need for the use of a condom if engaged in sexual activity with a
                  woman of childbearing potential during the entire period of treatment, even if
                  disruption of treatment and during 3 months after end of treatment.

               -  Agree to learn about the procedures for preservation of sperm before starting
                  treatment.

        Exclusion Criteria:

          -  IPSS low and intermediate-1

          -  Creatinine clearance with MDRD formula &lt; 30 ml/min

          -  Serum total bilirubin, or serum transaminases &gt; 3.0 x upper limit of normal (ULN)
             (except for unconjugated hyperbilirubinemia due to Gilbert's disease or secondary to
             MDS)

          -  Known hypersensitivity to the active substance or to any of the excipients of AZA

          -  History of severe congestive heart failure, clinically unstable cardiac or pulmonary
             disease

          -  Previous use of lenalidomide

          -  Previous treatment with hypomethylating agents

          -  Life-expectancy of less than six months because of another debilitating disease

          -  Uncontrolled invasive fungal infection at time of registration or active serious
             infection not controlled by oral or intravenous antibiotics

          -  Known positive for HIV or acute infectious hepatitis, type B or C

          -  Any serious medical condition or psychiatric illness that will prevent the subject
             from signing the informed consent form or will place the subject at unacceptable risk
             if he/she participates in the study.

          -  Active cancer or prior history of malignancy other than MDS (except basal cell or
             squamous cell carcinoma or carcinoma in situ of the cervix or breast) unless the
             subject has been free of disease for ≥ 3 years

          -  Pregnant or lactating females

          -  No affiliation to an insurance system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arsene MEKINIAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Antoine Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier FAIN, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Antoine Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre FENAUX, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arsene MEKINIAN, MD</last_name>
    <phone>+33 1 49 28 21 04</phone>
    <email>arsene.mekinian@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre FENAUX, PHD</last_name>
    <phone>+33 1 71 20 70 22</phone>
    <email>pierre.fenaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens cedex 01</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bérengère GRUSON, MD</last_name>
      <phone>+33 3 22 45 59 85</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bérengère GRUSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers cedex 9</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde HUNAULT-BERGER, PHD</last_name>
      <phone>+33 2 41 35 44 66</phone>
      <email>MaHunault@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde HUNAULT-BERGER, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Henri Duffaut d'Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bohrane SLAMA, MD</last_name>
      <phone>+33 4 32 75 93 94</phone>
      <email>bslama@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Bohrane SLAMA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BANOS, MD</last_name>
      <phone>+33 5 59 44 38 32</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne BANOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten BRAUN, MD</last_name>
      <phone>+33 1 48 95 70 51</phone>
      <email>thorsten.braun@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten BRAUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PARK, PHD</last_name>
      <phone>+33 4 76 76 62 77</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie PARK, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans cedex 09</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, MD</last_name>
      <phone>+33 2 43 43 43 61</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel LARIBI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno QUESNEL, PHD</last_name>
      <phone>+33 3 20 44 42 90</phone>
      <email>bruno.quesnel@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno QUESNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian ROSE, PHD</last_name>
      <phone>+33 3 20 87 45 32</phone>
      <email>rose.christian@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christian ROSE, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Pierre GOURIN, MD</last_name>
      <phone>+33 1 5 55 05 66 42</phone>
      <email>marie-pierre.gourin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre GOURIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert VEY, PHD</last_name>
      <phone>+33 1 4 91 22 36 95</phone>
      <email>veyn@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert VEY, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux cedex</city>
        <zip>77104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Loïc FOUILLARD, MD</last_name>
      <phone>+33 1 64 65 38 76</phone>
      <email>l-fouillard@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc FOUILLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre PETERLIN, MD</last_name>
      <phone>+33 2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre PETERLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1</name>
      <address>
        <city>Nice cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas CLUZEAU, MD</last_name>
      <phone>+33 4 92 03 58 44</phone>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas CLUZEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan WICKENHAUSER, MD</last_name>
      <phone>+33 4 66 68 32 31</phone>
      <email>stefanwickenhauser@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stefan WICKENHAUSER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FENAUX, PHD</last_name>
      <phone>+33 1 71 20 70 22</phone>
      <email>pierre.fenaux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FENAUX, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - Service de Médecine Interne</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arsène MEKINIAN, MD</last_name>
      <phone>+33 1 49 28 21 04</phone>
      <email>arsene.mekinian@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier FAIN, PHD</last_name>
      <phone>+33 1 49 28 21 04</phone>
      <email>olivier.fain@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arsène MEKINIAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <phone>+33 5 57 65 65 11</phone>
      <email>sophie.dimicoli-salazar@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric WATTEL, PHD</last_name>
      <phone>+33 4 72 11 74 01</phone>
      <email>eric.wattel@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric WATTEL, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale CONY-MAKHOUL, MD</last_name>
      <phone>+33 1 4 50 63 64 31</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale CONY-MAKHOUL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <phone>+33 1 2 32 08 22 88</phone>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile BEYNE-RAUZY, PHD</last_name>
      <phone>+33 1 5 31 15 62 64</phone>
      <email>beynerauzy.odile@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Odile BEYNE-RAUZY, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnès GUERCI-BRESLER, MD</last_name>
      <phone>+33 1 3 83 15 32 81</phone>
      <email>a.guerci@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Agnès GUERCI-BRESLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>November 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azacitidine</keyword>
  <keyword>MDS</keyword>
  <keyword>Systemic auto-immune and inflammatory disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
